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Cognitive Performance and Mood Changes 
in the Post-thyroidectomy Patient Treated with T4 versus T4+T3
Lorena Likaj, MPH
Abstract
This study investigated changes in cognition and mood 
in the post-thyroidectomy patient. Specifically, this 
study investigates changes in cognition and mood, 
when the patient has been returned to normal, 
laboratory serum thyroid-stimulating hormone (TSH) 
reference levels, following conventional thyroid 
hormone replacement therapies with levothyroxine 
(T4) alone. Findings reveal a distinct, small, and 
clinically significant subgroup of post-thyroidectomy 
patients (10–15%) who continue to experience 
impaired cognition and mood, even when routinely 
measured serum TSH levels have been returned to 
normal levels. Findings are discussed within a 
conceptual matrix emphasizing the differential role of 
deiodinase enzymes required for conversion of T4 to 
T3 within the brain (Type II), compared to T4 to T3 
conversion completed in peripheral tissues. 
Procedures
A systematic review of the professional medical 
literature was used to summarize existing knowledge, 
test specific research questions, and evaluate the 
proposed model. 
Seven studies, meeting specific inclusion and 
exclusion criteria, were selected as representative of 
all studies identified by the systematic review and are 
presented here.
Research Questions
1. Do post-thyroidectomy patients, who have been 
returned to normal thyroid stimulating hormone 
levels, by way of conventional hormone 
replacement therapies, continue to experience 
impairments in cognition and mood?
2. Can differences in the post-thyroidectomy patients, 
who continue to experience impaired cognition and 
mood, be explained by the hormone replacement 
therapy intervention, T4 alone versus T4 in 
combination with T3?
3. Does review, summary, and critical analysis of the 
professional medical literature, from the period 
1985- 2015, support a proposed new model, 
emphasizing down regulation of deiodinase 
enzymes type II in brain, as potentially causal in 
explaining differences between post-thyroidectomy 
patient who’s cognition and mood improves with 
conventional hormone replacement therapies (80-
85%) and post-thyroidectomy patients, who fail to 
demonstrate significant improvements in cognition 
and mood?
Purpose
The purpose of this study is to investigate changes in 
mood and cognitive function in post thyroidectomy 
patients.  The reason this study is important is 
because there are few studies that investigate 
treatment of hypothyroidism in the post thyroidectomy 
patient.
Problem
Many patients with hypothyroidism, induced by a 
complete thyroidectomy, develop depression, 
decrease in cognitive function, and other psychiatric 
symptoms. These symptoms are reversed with 
thyroxine (T4) replacement therapy.
In these patients, the standard of treatment is daily 
administration of levothyroxine, a synthetic form of 
thyroxine (T4). The administration of T4 replaces the 
low levels of T4 resulting from the surgical destruction 
of the thyroid gland. The administered T4 is then 
converted to T3 peripherally and in the brain through 
the usual processes.
Of interest to us is the fact that, despite treatment and 
achievement of euthyroid levels as measured by 
routine plasma levels, 10-15 % of patients continue to 
experience a decrease in cognitive function and 
depression despite normal serum concentration of T4 
and T3. 
Relevant Literature
Social Change Implications
This study proposes a new model, based upon down 
regulation of enzymes responsible for the conversion 
of T4 into T3. This model has the following social 
change implications: 
1. Improve the medical management of post-
thyroidectomy patients.
2. Improve the quality of life and standard of living of 
post-thyroidectomy patients and their families. 
Limitations
This investigation is a systematic review of the 
literature and limited only by the constraints of the 
research design. 
Conclusions
The use of T4 in combination with T3, in restoring 
post-thyroidectomy patients to an euthyroid state, is 
controversial among clinicians. Data from this review 
reveal :
1. 10-15% of post-thyroidectomy patients evidence 
impairment in cognition and mood, despite serum TSH 
levels being returned to normal reference value levels 
on T4 therapy alone. 
2. Treatment with T4+T3 generates more favorable 
results than treatment with T4 alone. 
3. Data support the proposed model of down 
regulation of deiodinase enzyme type II in brain, as 
casual in explaining differences
Findings
This study was funded in its entirety by Saint James School of Medicine – Anguilla, BWI, by a 
small internal research grant #2015-06.
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Figure 1. Percentage of patients evidencing no impairment and impaired cognition 
or mood, following thyroidectomy, when serum thyroid values have been returned to 
normal reference values. N = 397, Not impaired = 85%, Impaired = 15%, p < 0.05. 
Original data extracted and reanalyzed from Bianco, A. and Casula, S. (2012).[1]
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Figure 2.  Percentage of patients evidencing no impairment and impaired cognition 
and mood, thyroidectomy, when serum thyroid values have been returned to normal 
reference values. Not impaired = 90%, Impaired = 10%, p < 0.05. Original data 
extracted and reanalyzed from Wiersinga (2014).[2]
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Figure 3.  Correctly matched number and symbol - paired recall. Normal 
performance is 6 or more, with a maximum possible score of 9. N = 15 women 
patients with hypothyroidism, treated originally with T4 alone, and then treated with 
T4 + T3. Original data extracted and reanalyzed from Bunevicius and Prange 
(2000).[4] Paired t-test T4 with T4+ T3, p < 0.02.
Figure 4.  Beck Depression Inventory scores greater than 10 are associated with 
impaired and depressed mood. N = 59 patients with autoimmune hypothyroidism on 
stable T4 treatment times six months, and then treated with T4+T3. Randomized, 
double blind. cross-over, experimental research design. Original data extracted and 
reanalyzed from Nygaard, Jensen, Kvetny, et. al. (2009).[8] Paired t- test T4 with T4 + 
T3, p < 0.01.
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